Trending Topic

3D Rendered Medical Illustration of Male Anatomy - Colon Cancer; Ascending Colon.
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS […]

Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 22nd 2021

We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab.

The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation’ was presented at the 2021 ASCO Annual Meeting.

Abstract number: TPS8052 

Clinical Trial Registration

DOI: 10.1200/JCO.2021.39.15_suppl.TPS8052 Journal of Clinical Oncology 39, no. 15_suppl

Questions
1. What are the potential advantages and challenges of developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab? (0:15-02:00)
2. What are the aims of the EQUATE trial and which patients will be eligible for enrolment? (02:00-03:30)
3. Could you tell us a little about the randomized biomarker-stratified design of the study? (03:30-04:32)
4. How have the subgroup sizes been calculated and what is the total accrual goal? (04:32-05:33)
5. What is the primary endpoint of the study? (05:33-06:36)

Disclosures: Dr Shaji Kumar discloses research funding for clinical trials to his institution from Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Astra-Zeneca, Novartis, Roche-Genentech, Takeda and Tenebio. He also discloses consulting and advisory board participation (with no personal payments) for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, KITE, Astra-Zeneca and Bluebird Bio; and with personal payment for Oncopeptides, Beigene, Antengene.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.

Filmed in coverage of the 2021 ASCO Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup